Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

Saved in:
Bibliographic Details
Published in:Skin (Milwood, N.Y.) N.Y.), 2022-11, Vol.6 (6), p.s62
Main Authors: Armstrong, April W, Hee Park, Sang, Chirikov, Viktor, Nicolas, Pierre, Wang, Wei-Jhih, Colombo, Matthew J, Patel, Vardhaman
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2574-1624
2574-1624
DOI:10.25251/skin.6.supp.62